TAIHO VENTURES — ESTABLISHED 2016
Ten years on biology’s clock.
The corporate venture arm of Taiho Pharmaceutical. Four hundred million dollars under management. Twenty-three active positions. One strategic buyer named on day one.
Read the Cullinan Pearl case →A CASE
How a 2019 term sheet became Cullinan Pearl.
In the summer of 2019, a small team at Cullinan Oncology was working on a project that, on paper, looked like every other early‑stage build. A single asset. A single mechanism. A Phase I sketch that had not yet been written.
Most venture funds did not take the meeting. A few did, and asked the usual questions about dilution and exit multiples. One did something different. Taiho Ventures asked what the molecule was, and how the chemistry team in Tsukuba could help. The conversation went on for an afternoon. The term sheet that came out of it had an option written into it — not as a closing trick, but as the architecture of the relationship.
Six years later the asset cleared a Phase II readout, and Taiho Pharmaceutical exercised the option. The transaction had a name. The model that produced it was older than the name. It is what happens when a strategic partner is willing to underwrite a molecule on biology’s clock, not a fund’s.
METHOD
Three things a Phase II company finds here that it cannot find in a syndicate.
- I
Patience as a method, not a virtue.
Ten years on the same cap table is not a virtue. It is a method. Therapeutics do not let you sprint; a molecule clears Phase I or it does not, and biology is unmoved by fund cycles. We are set up to live on that timeline.
- II
A Japanese pharma that calls when the Phase II reads.
The conversation with our chemistry team in Tsukuba opens when a Phase II readout does. We are not the partner who sets your IPO calendar. We are the partner who can answer one question — does this molecule work in vivo, and can we help it work better.
- III
The option, written down on day one.
The path to a strategic acquirer is written into the term sheet from the day the founder signs. Cullinan Pearl is the proof point. Most syndicates can offer capital. Few can offer a strategic buyer named on day one.
PORTFOLIO
Twenty-three positions, each on its own clock.
Anavo TherapeuticsFibrosis, by the TGFβ pathway.
Arcus BiosciencesImmuno‑oncology, syndicate co‑developer.
Breakpoint TherapeuticsDNA damage response, before the break.
cellvieMitochondrial transplantation, taken seriously.
Cullinan OncologyThe build‑to‑buy proof point, on the record.
Delphia TherapeuticsSynthetic lethality, narrowed.
Dren BioTargeted protein degradation, antibody-led.
EpiBiologicsTargeted protein degradation, on the surface.
Halda TherapeuticsA new degrader for prostate cancer.
Harpoon TherapeuticsT‑cell engagers, conditionally on.
Incendia TherapeuticsInflammation’s missing target class.
LiberoTheraGPCR antibodies, made tractable.
Light Horse TherapeuticsThe undruggable, by structural genomics.
Magnet BiomedicineMolecular glues, by design.
NextCureImmune checkpoints beyond PD‑1.
NormunityRestoring immune set‑points.
ORIC PharmaceuticalsOvercoming resistance, by mechanism.
Orna TherapeuticsCircular RNA, in vivo.
STORM TherapeuticsRNA‑modifying enzymes, as targets.
TheolyticsOncolytic viruses, intratumoral.
Transition BioCondensate biology, as a drug class.
VerteroStealth‑mode small molecules.
Werewolf TherapeuticsConditionally activated cytokines.
INVESTMENT
What we underwrite.
Research to Pre‑IND is where the relationship begins. IND to PoC is opportunistic, and is usually a chemistry conversation before it is a cap‑table conversation.
- Sectors
- Drug discovery, first‑in‑class or new biology.
- Innovative platform technologies for drug discovery.
- Spin‑out opportunities from Taiho pipelines.
- Medical device, diagnostics, digital health (opportunistic).
- Therapeutic areas
- Oncology.
- Non‑oncology — immunology, allergy, bone, muscle, orphan.
- Modalities
- Small molecules.
- Biologics.
- Gene and cell therapy.
- Stage
- Research to Pre‑IND.
- IND to PoC (opportunistic).
CONTACT
Tell us about the molecule.
A deck is not what we need first. What we need is to know what the asset is, what biology it touches, and whether a Phase II partner who can answer in Tsukuba would be useful to the team.
Start the correspondence →TAIHO · SEAL